CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hubei Minkang Pharmaceutical Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hubei Minkang Pharmaceutical Ltd
55 Ubi Ave, #03-01, Mintwell Building
Phone: +65 67477883p:+65 67477883 408864  Singapore Ticker: NXPE NXPE

This company ceased filing statements with the SEC on 3/31/2015.

Business Summary
Hubei Minkang Pharmaceutical Ltd. (Hubei), through its subsidiaries, HBMK Pharmaceutical Limited (HBMK) and Hubei Minkang PRC, produces and markets traditional Chinese medicines (TCM). The Company’s products include product types include pills, tablets, capsules, granules, oral liquids, syrups, mixtures and injections and dosages. It markets its products to the United States, Japan, Canada, Singapore, Malaysia, Thailand and Hong Kong. The Company’s principal Chinese products include Yinxing Damo Zhusheye, An Ka Huangmin Jiaonang, Xumeian Capsule, Wei C Yinqiao Pian and Shuxin Koufouye. Hubei Minkang PRC’s selling product, Wei C is approved by the United States Food and Drug Administration (FDA) for sale in the United States. Hubei Minkang PRC markets its products in approximately 26 provinces in China, and has a distribution network which covers over 1200 hospitals and 10100 medical halls (TCM pharmacies).
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201412/31/2013YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
7384 Photofinishing laboratories

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Chief Financial Officer, Director Tong Tai T.Lee 62 6/19/2013 9/21/2011
Treasurer, Secretary, Director Siew Khim K.Ang 40 9/21/2011 9/21/2011

Business Names
Business Name
Blackrock Petroleum Corp.
HBMK
HBMK Pharmaceutical Limited
Nexgen Petroleum Corp
Nexgen Petroleum Corp.
NXPE

General Information
Outstanding Shares: 52,189,045 (As of 11/14/2014)
Shareholders: 96
Stock Exchange: OTC
Federal Tax Id: 262410685


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023